KAWAS LEEN 4
4 · Athira Pharma, Inc. · Filed Feb 22, 2021
Insider Transaction Report
Form 4
KAWAS LEEN
DirectorPresident & CEO10% Owner
Transactions
- Award
Stock Option (Right to Buy)
2021-02-18+231,000→ 231,000 totalExercise: $21.15Exp: 2031-02-17→ Common Stock (231,000 underlying)
Footnotes (1)
- [F1]One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter.